Business Context and Reporting Period
Cytosorbents Corp, a Delaware corporation, filed this Form 8-K on April 11, 2017, to report the closing of an additional share sale. The filing relates to the full exercise of an over-allotment option granted in connection with a follow-on offering that initially closed on April 5, 2017.
Key Financial Metrics
- Shares Sold: 333,333 shares of common stock.
- Offering Price: $4.50 per share.
- Gross Proceeds: Approximately $1,500,000.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operational or balance sheet metrics.
Material Changes
The primary material change is the increase in outstanding common stock and cash assets resulting from the underwriters' full exercise of the 30-day over-allotment option. This transaction added 333,333 shares to the initial 2,222,222 shares sold in the follow-on offering.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a procedural report confirming the completion of a capital raise event.
Investor Verification Checklist
- Verify the total number of shares outstanding post-closing of the over-allotment.
- Confirm the net proceeds after deducting underwriting discounts and commissions, as only gross proceeds are stated.
- Review the initial April 5, 2017 offering documents to understand the full context of the follow-on offering.